Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))

Jordi Bruix, Ann Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis, Josep Llovet

Research output: Contribution to journalComment/debate

4 Scopus citations

Abstract

It has come to our attention that there are errors in the symbols used in the bottom two rows of Table 2 and the bottom row of Table 3. Please see the corrected Tables below. Please also note that in the online supplementary information there was a similar error in the bottom row of Table S1. An updated online supplementary file is provided with this corrigendum.

Original languageEnglish
Pages (from-to)990-991
Number of pages2
JournalJournal of Hepatology
Volume69
Issue number4
DOIs
StatePublished - Oct 2018

Fingerprint

Dive into the research topics of 'Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))'. Together they form a unique fingerprint.

Cite this